Citi expects the recent weakness in this drugmaker to be a ‘buying opportunity’

Of the 30 analysts that have coverage on Divi’s Laboratories, 11 have a “buy” rating, six have a “hold” rating and 13 have a “sell” rating.

Leave a Reply

Your email address will not be published. Required fields are marked *